Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Sponsor: Hunan Province Tumor Hospital
This observational or N/A phase trial investigates Non-small Cell Lung Cancer and is currently actively recruiting participants. Hunan Province Tumor Hospital leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Feb 2025 — Present [monthly]
Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jan 2024 — Jul 2024 [monthly]
Recruiting
-
Apr 2022 — Jan 2024 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Recruiting
-
Apr 2020 — Jan 2021 [monthly]
Recruiting
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hunan Province Tumor Hospital
For direct contact, visit the study record on ClinicalTrials.gov .